Literature DB >> 27443286

BNIP3L in myelodysplastic syndromes and acute myeloid leukemia: impact on disease outcome and cellular response to decitabine.

Mariana Lazarini1,2, João Agostinho Machado-Neto3, Adriana da Silva Santos Duarte3, Fernando Vieira Pericole3, Karla Priscila Vieira3, Fernanda S Niemann3, Marisa Alvarez3, Fabiola Traina3,4, Sara Teresinha Olalla Saad1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27443286      PMCID： PMC5394857          DOI： 10.3324/haematol.2016.142521

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

Review 1.  Autophagy in the pathogenesis of myelodysplastic syndrome and acute myeloid leukemia.

Authors:  Alexander Scarth Watson; Monika Mortensen; Anna Katharina Simon
Journal:  Cell Cycle       Date:  2011-06-01       Impact factor: 4.534

2.  Abnormal Hedgehog pathway in myelodysplastic syndrome and its impact on patients' outcome.

Authors:  Juliana M Xavier-Ferrucio; Fernando Vieira Pericole; Matheus Rodrigues Lopes; Paulo Latuf-Filho; Karin Spät Albino Barcellos; Amanda Inácio Dias; Paula de Melo Campos; Fabiola Traina; Jose Vassallo; Sara Teresinha Olalla Saad; Patricia Favaro
Journal:  Haematologica       Date:  2015-08-20       Impact factor: 9.941

3.  NIX is required for programmed mitochondrial clearance during reticulocyte maturation.

Authors:  Rachel L Schweers; Ji Zhang; Mindy S Randall; Melanie R Loyd; Weimin Li; Frank C Dorsey; Mondira Kundu; Joseph T Opferman; John L Cleveland; Jeffery L Miller; Paul A Ney
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-29       Impact factor: 11.205

4.  HIF-1α can act as a tumor suppressor gene in murine acute myeloid leukemia.

Authors:  Talia Velasco-Hernandez; Axel Hyrenius-Wittsten; Matilda Rehn; David Bryder; Jörg Cammenga
Journal:  Blood       Date:  2014-09-29       Impact factor: 22.113

5.  Stathmin 1 is involved in the highly proliferative phenotype of high-risk myelodysplastic syndromes and acute leukemia cells.

Authors:  João Agostinho Machado-Neto; Paula de Melo Campos; Patricia Favaro; Mariana Lazarini; Irene Lorand-Metze; Fernando Ferreira Costa; Sara Teresinha Olalla Saad; Fabiola Traina
Journal:  Leuk Res       Date:  2013-12-01       Impact factor: 3.156

Review 6.  Epigenetic Therapy in Acute Myeloid Leukemia: Current and Future Directions.

Authors:  Tae Kon Kim; Steven D Gore; Amer M Zeidan
Journal:  Semin Hematol       Date:  2015-04-08       Impact factor: 3.851

7.  Essential role for Nix in autophagic maturation of erythroid cells.

Authors:  Hector Sandoval; Perumal Thiagarajan; Swapan K Dasgupta; Armin Schumacher; Josef T Prchal; Min Chen; Jin Wang
Journal:  Nature       Date:  2008-05-04       Impact factor: 49.962

Review 8.  Myelodysplastic syndromes.

Authors:  Lionel Adès; Raphael Itzykson; Pierre Fenaux
Journal:  Lancet       Date:  2014-03-21       Impact factor: 79.321

9.  Aberrant DNA methylation associated with silencing BNIP3 gene expression in haematopoietic tumours.

Authors:  M Murai; M Toyota; A Satoh; H Suzuki; K Akino; H Mita; Y Sasaki; T Ishida; L Shen; G Garcia-Manero; J-P J Issa; Y Hinoda; T Tokino; K Imai
Journal:  Br J Cancer       Date:  2005-03-28       Impact factor: 7.640

10.  Hif-1α and Hif-2α synergize to suppress AML development but are dispensable for disease maintenance.

Authors:  Milica Vukovic; Amelie V Guitart; Catarina Sepulveda; Arnaud Villacreces; Eoghan O'Duibhir; Theano I Panagopoulou; Alasdair Ivens; Juan Menendez-Gonzalez; Juan Manuel Iglesias; Lewis Allen; Fokion Glykofrydis; Chithra Subramani; Alejandro Armesilla-Diaz; Annemarie E M Post; Katrin Schaak; Deniz Gezer; Chi Wai Eric So; Tessa L Holyoake; Andrew Wood; Dónal O'Carroll; Peter J Ratcliffe; Kamil R Kranc
Journal:  J Exp Med       Date:  2015-12-07       Impact factor: 14.307
View more
  7 in total

1.  BNIP3L/NIX degradation leads to mitophagy deficiency in ischemic brains.

Authors:  Xiaoli Wu; Yanrong Zheng; Mengru Liu; Yue Li; Shijia Ma; Weidong Tang; Wenping Yan; Ming Cao; Wanqing Zheng; Lei Jiang; Jiaying Wu; Feng Han; Zhenghong Qin; Liang Fang; Weiwei Hu; Zhong Chen; Xiangnan Zhang
Journal:  Autophagy       Date:  2020-08-12       Impact factor: 16.016

2.  Down-regulation of miR-29c is a prognostic biomarker in acute myeloid leukemia and can reduce the sensitivity of leukemic cells to decitabine.

Authors:  Li-Juan Tang; Guo-Kang Sun; Ting-Juan Zhang; De-Hong Wu; Jing-Dong Zhou; Bei-Bei Ma; Zi-Jun Xu; Xiang-Mei Wen; Qin Chen; Dong-Ming Yao; Jun Qian; Ji-Chun Ma; Jiang Lin
Journal:  Cancer Cell Int       Date:  2019-07-10       Impact factor: 5.722

Review 3.  BNIP3L/NIX-mediated mitophagy: molecular mechanisms and implications for human disease.

Authors:  Yue Li; Wanqing Zheng; Yangyang Lu; Yanrong Zheng; Ling Pan; Xiaoli Wu; Yang Yuan; Zhe Shen; Shijia Ma; Xingxian Zhang; Jiaying Wu; Zhong Chen; Xiangnan Zhang
Journal:  Cell Death Dis       Date:  2021-12-20       Impact factor: 8.469

4.  Impaired Mitophagy of Nucleated Erythroid Cells Leads to Anemia in Patients with Myelodysplastic Syndromes.

Authors:  Huijuan Jiang; Liyan Yang; Lifang Guo; Ningbo Cui; Gaochao Zhang; Chunyan Liu; Limin Xing; Zonghong Shao; Huaquan Wang
Journal:  Oxid Med Cell Longev       Date:  2018-06-03       Impact factor: 6.543

5.  DNA methylation of the promoter region of bnip3 and bnip3l genes induced by metabolic programming.

Authors:  Vincent Veron; Lucie Marandel; Jingwei Liu; Emilio J Vélez; Olivier Lepais; Stéphane Panserat; Sandrine Skiba; Iban Seiliez
Journal:  BMC Genomics       Date:  2018-09-17       Impact factor: 3.969

Review 6.  Mitochondria and Their Relationship with Common Genetic Abnormalities in Hematologic Malignancies.

Authors:  Ibolya Czegle; Austin L Gray; Minjing Wang; Yan Liu; Jun Wang; Edina A Wappler-Guzzetta
Journal:  Life (Basel)       Date:  2021-12-07

7.  Expression and Clinical Significance of BCL2 Interacting Protein 3 Like in Multiple Myeloma.

Authors:  Ruolin Li; Gang Chen; Yiwu Dang; Rongquan He; Angui Liu; Jie Ma; Zhian Ling
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.